Posted by Michael Wonder on 27 Apr 2022
Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia
27 April 2022 - NICE has published evidence-based recommendations on the use of venetoclax in combination with low dose cytosine arabinoside for adults with untreated acute myeloid leukaemia.
Venetoclax, when used in combination with low dose cytosine arabinoside, is recommended as an option for adults with untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable, only if they have over 30% bone marrow blasts and AbbVie provides venetoclax according to the commercial arrangement.
